(05 Feb 2021) Hydroxychlooquine- No beneficial effect or significant harm

HYDROXYCHLOROQUINE FOR THE TREATMENT OF SEVERE RESPIRATORY INFECTION BY COVID-19: A RANDOMIZED CONTROLLED TRIAL

https://www.medrxiv.org/content/10.1101/2021.02.01.21250371v1

NCT04315896- A total of 214 patients with COVID-19 were recruited, randomized and analyzed. They were hypoxemic with a mean SpO₂ of 65% ± 20, tachycardic (pulse rate 108±17 min-¹) and tachypneic (32 ±10 min-¹); 162 were under mechanical ventilation at randomization. Thirty-day mortality was similar in both groups (38% in Hydroxychloroquine vs. 41% in placebo, hazard ratio [HR] 0.88, 95% Confidence Interval [95%CI] 0.51-1.53). In the surviving participants, no significant difference was found in secondary outcomes. No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.